Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Assignees
MemberIntralytixIntralytixIntralytix is a biotechnology company specializing in bacteriophage-based solutions for controlling pathogenic bacteria in food safety, human and animal health, dietary supplements, environmental sanitation, and veterinary applications. The company utilizes lytic bacteriophages for targeted, non-chemical interventions and operates with in-house cGMP manufacturing, a broad patent portfolio, and ongoing clinical research, applying AI and machine learning in phage discovery and process optimization. Intralytix supports industry and academic progress through conference sponsorships and collaborative projects.
Intralytix is a biotechnology company specializing in bacteriophage-based solutions for controlling pathogenic bacteria in food safety, human and animal health, dietary supplements, environmental sanitation, and veterinary applications. The company utilizes lytic bacteriophages for targeted, non-chemical interventions and operates with in-house cGMP manufacturing, a broad patent portfolio, and ongoing clinical research, applying AI and machine learning in phage discovery and process optimization. Intralytix supports industry and academic progress through conference sponsorships and collaborative projects.
Publication Number
US-10711252-B2
Publication Date
2020-07-14
Expiration Date
Abstract
The present invention is directed to isolated bacteriophages having specificity and lytic activity against strains of Shigella species, methods of using the bacteriophages, progeny and derivatives derived therefrom, to control the growth of Shigella species in various settings (e.g., food safety, sanitation, modulating microbiome, prebiotics, probiotics).
Core Innovation
The invention relates to nine deposited lytic Shigella-specific bacteriophages, and progeny, variants, and derivatives thereof. The deposited phages include SHFML-26, SHFML-11, SHSML-45, SHSML-52-1, SHBML-50-1, SHBML-50-2, SHSML-52-2, SHSML-36, and SHFML-21, each associated with listed ATCC deposit accessions. The disclosed progeny, variants, and derivatives retain phenotypic and lytic specificity against Shigella species and/or strains.
The invention is directed to compositions comprising the deposited Shigella lytic bacteriophages and their progeny, variants, or derivatives, including pharmaceutical and non-pharmaceutical compositions. The compositions are described for preventing and/or treating Shigella infection and/or colonization, including microbiome modulation, and for controlling Shigella in food and food-processing environments. The disclosed compositions include formulated formats such as powders, capsules, and syrups and may include carriers, stabilizers, and excipients.
The disclosure also includes applications for controlling environmental biofilms and for detection systems to identify viable Shigella cells. Detection is described using phage-derived or recombinant phage reporters, including luciferase/luxAB, and metabolism readouts including ATP and adenosine kinase (AK). The document further supports the disclosed specificity and lytic activity by describing profiling and lytic specificity testing against targeted Shigella strains and minimal lysis of non-Shigella strains.
Claims Coverage
Not explicitly described in patent.
Not explicitly described in patent.
Stated Advantages
Documented Applications
Preventing and/or treating Shigella infection and/or colonization, including microbiome modulation.
Controlling Shigella in food and food-processing environments, including equipment, surfaces, paper products, wipes, films, and refrigerated devices.
Environmental biofilm control involving Shigella.
Detection systems to identify viable Shigella cells using phage-derived or recombinant phage reporters, including luciferase/luxAB, and metabolism readouts including ATP and adenosine kinase (AK).
Interested in licensing this patent?